Literature DB >> 28726335

Preperitoneal fat as a non-invasive marker of increased risk of severe non-alcoholic fatty liver disease in patients with type 2 diabetes.

Daniella Braz Parente1,2, Jaime Araújo Oliveira Neto1, Pedro Emmanuel Alvarenga Americano Brasil1, Fernando Fernandes Paiva3, José Pedro Rodrigues Ravani1, Marilia Brito Gomes4, Valeria Lanzoni5, Carlos Frederico Ferreira Campos4, Lilian Machado-Silva4, Renata Mello Perez1,2,4, Rosana Souza Rodrigues1,2.   

Abstract

BACKGROUND AND AIM: Fat distribution may have prognostic value in the evaluation of non-alcoholic fatty liver disease. This study was conducted to evaluate associations of magnetic resonance imaging-measured abdominal fat areas with steatosis, steatohepatitis, and fibrosis, assessed histopathologically, in patients with type 2 diabetes.
METHODS: This prospective study included 66 patients with type 2 diabetes (12 males, 54 females, age 26-68 years), without chronic liver disease of other causes. Axial dual-echo magnetic resonance images were acquired. Visceral, subcutaneous, and preperitoneal fat areas were measured using Osirix software. Liver biopsy specimens were obtained from all patients and examined histopathologically to evaluate steatosis, steatohepatitis, and fibrosis. Linear (for steatosis) and logistic (for steatohepatitis and fibrosis) regression models were fitted for the outcomes. R2 was used as a measure of how much model variance the predictors explained and to compare different predictors of the same outcome.
RESULTS: Visceral and preperitoneal fat areas correlated well with histopathologically determined liver steatosis grade (both P = 0.004) and liver fibrosis (P = 0.008 and P = 0.037, respectively). All fat areas correlated well with steatohepatitis (P ≤ 0.002). Preperitoneal and visceral fat areas were the best predictors of steatohepatitis (R2 = 0.379) and fibrosis (R2 = 0.181), respectively.
CONCLUSIONS: Visceral fat area was the best predictor of fibrosis in patients with type 2 diabetes. Preperitoneal fat area was the best predictor of steatohepatitis and is a potential new non-invasive marker for use in the screening of these patients to detect more aggressive forms of non-alcoholic fatty liver disease.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  liver biopsy; non-alcoholic fatty liver disease; preperitoneal fat; steatohepatitis; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 28726335     DOI: 10.1111/jgh.13903

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Authors:  E Cipponeri; N Vitturi; V Mariano; F Boscari; S Galasso; C Crepaldi; G P Fadini; S Vigili de Kreutzenberg; M C Marescotti; E Iori; F Cavallin; L Sartori; A Baritussio; A Avogaro; D Bruttomesso
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

2.  Body composition measured by bioelectrical impedance analysis is a viable alternative to magnetic resonance imaging in children with nonalcoholic fatty liver disease.

Authors:  Sarah Orkin; Toshifumi Yodoshi; Emily Romantic; Kathryn Hitchcock; Ana Catalina Arce-Clachar; Kristin Bramlage; Qin Sun; Lin Fei; Stavra A Xanthakos; Andrew T Trout; Marialena Mouzaki
Journal:  JPEN J Parenter Enteral Nutr       Date:  2021-04-30       Impact factor: 4.016

3.  Magnetic Resonance Imaging Assessment of Abdominal Ectopic Fat Deposition in Correlation With Cardiometabolic Risk Factors.

Authors:  Qin-He Zhang; Lu-Han Xie; Hao-Nan Zhang; Jing-Hong Liu; Ying Zhao; Li-Hua Chen; Ye Ju; An-Liang Chen; Nan Wang; Qing-Wei Song; Li-Zhi Xie; Ai-Lian Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-30       Impact factor: 5.555

4.  Evaluation of the predictive value of body mass index (BMI), waist circumference, and visceral fat to differentiate non-alcoholic fatty liver (NAFLD) in women with polycystic ovary syndrome.

Authors:  Bita Eslami; Najmeh Aletaha; Arezoo Maleki-Hajiagha; Mahdi Sepidarkish; Ashraf Moini
Journal:  J Res Med Sci       Date:  2022-05-30       Impact factor: 1.985

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.